Federated Hermes, Inc. Clovis Oncology, Inc. Transaction History

Federated Hermes, Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.7 - $4.76 $54,523 - $96,123	-20,194 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$4.06 - $5.8 $77,253 - $110,362	19,028 Added 1631.9%	20,194 $90,000
Q2 2021 Aug 16, 2021	SELL	$5.02 - $7.05 $5 - $7	-1 Reduced 0.09%	1,166 $7,000
Q1 2021 May 13, 2021	BUY	$4.81 - $10.34 $3,092 - $6,648	643 Added 122.71%	1,167 $8,000
Q4 2020 Feb 12, 2021	SELL	$4.13 - $6.41 $1,115 - $1,730	-270 Reduced 34.01%	524 $3,000
Q3 2020 Nov 12, 2020	SELL	$4.82 - $7.72 $101 - $162	-21 Reduced 2.58%	794 $5,000
Q2 2020 Aug 13, 2020	SELL	$5.69 - $9.69 $284 - $484	-50 Reduced 5.78%	815 $6,000
Q1 2020 May 13, 2020	SELL	$3.77 - $11.0 $741,585 - $2.16 Million	-196,707 Reduced 99.56%	865 $6,000
Q4 2019 Feb 14, 2020	SELL	$3.0 - $16.43 $124,569 - $682,222	-41,523 Reduced 17.37%	197,572 $2.06 Million
Q3 2019 Nov 14, 2019	BUY	$3.93 - $15.35 $907,024 - $3.54 Million	230,795 Added 2780.66%	239,095 $940,000
Q1 2018 May 09, 2018	SELL	$50.12 - $67.72 $385,924 - $521,444	-7,700 Reduced 48.13%	8,300 $438,000
Q4 2017 Feb 14, 2018	BUY	$57.69 - $84.58 $346,140 - $507,480	6,000 Added 60.0%	16,000 $0
Q3 2017 Nov 13, 2017	BUY	$67.17 - $84.81 $671,700 - $848,100	10,000	10,000 $824,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.